Otonomy (OTIC) – FDA
-
Otonomy (OTIC) Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
-
Otonomy (OTIC) Says Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus Demonstrated No Clinically Meaningful Benefit Versus Placebo
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to OTIC Stock Lookup